Clover Health Investments, Corp. 8-K Summary
Business Context and Reporting Period
Clover Health Investments, Corp. filed a Form 8-K dated June 7, 2023, reporting results of its 2023 Annual Meeting of Stockholders, held virtually on June 7, 2023. Class A and Class B common stock voted together; Class A shares carried one vote per share and Class B shares carried ten votes per share. The voting record date was April 14, 2023.
Financial and Operating Metrics
This filing reports corporate-governance matters only. It does not provide revenue, profit, cash flow, margins, debt, liquidity, operating metrics, or other financial results.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial or operating information. The principal reported changes are the election of two Class II directors and stockholder ratification of the independent accounting firm for fiscal year 2023.
Meeting Results, Outlook, and Risks
- Director elections: Demetrios L. Kouzoukas was elected with 937,464,810 votes for, 18,224,158 withheld, and 123,427,586 broker non-votes. Andrew Toy was elected with 939,487,709 votes for, 16,201,259 withheld, and 123,427,586 broker non-votes. Both will serve until the 2026 annual meeting and until successors are qualified.
- Executive compensation advisory vote: Stockholders approved, on a non-binding advisory basis, the compensation of the named executive officers for 2022, with 938,847,123 votes for, 15,400,898 against, 1,440,947 abstentions, and 123,427,586 broker non-votes.
- Independent auditor: Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 1,074,118,616 votes for, 3,280,363 against, and 1,717,575 abstentions.
- The filing contains no management financial guidance, operating outlook, material contingencies, or unusual financial items.
Important Facts for Investors to Verify
- Confirm the continued board service terms of Kouzoukas and Toy through the 2026 annual meeting.
- Review the proxy statement filed April 26, 2023 for director backgrounds, executive compensation details, and voting mechanics.
- Assess subsequent filings for financial results, liquidity, debt, business outlook, and any developments involving Ernst & Young LLP.
- Note that broker non-votes affected the director and compensation proposals but were not reported for the auditor-ratification proposal.